• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Envista Holdings Corporation

    5/30/25 4:39:21 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care
    Get the next $NVST alert in real time by email
    SD 1 nvst2025sdconflictminerals.htm SD Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549  
     
    FORM SD
    Specialized Disclosure Report
     
    envistalogoa25a.jpg
    ENVISTA HOLDINGS CORPORATION
    (Exact Name of Registrant as Specified in Charter)  
     
     
    Delaware001-3905483-2206728
    (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification Number)
    200 S. Kraemer Blvd., Building E92821-6208
    Brea,California
    (Address of Principal Executive Offices)(Zip Code)
    Mark Nance 714-817-7000
    (Name and telephone number, including area code, of the person to contact in connection with this report)  
     
    Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:
     
     ☒Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.
    ☐Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended _______.
     
    image_0a.jpg




    Section 1 — Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    Conflict Minerals Disclosure
    This Form SD of Envista Holdings Corporation (the “Company”) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2024 to December 31, 2024.
    A copy of the Company’s Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD, and is publicly available at www.envistaco.com under the “Investors” caption and “Filings & Reports” subcaption.
    Rule 13p-1 (the “Rule”) requires disclosure of certain information when a company manufactures or contracts to manufacture products for which the minerals specified in the Rule are necessary to the functionality or production of those products. The specified minerals are gold, columbite-tantalite (coltan), cassiterite and wolframite, including their derivatives, which are limited to tantalum, tin and tungsten (the “Conflict Minerals”). The “Covered Countries” for the purposes of the Rule are the Democratic Republic of the Congo, the Republic of the Congo, the Central African Republic, South Sudan, Uganda, Rwanda, Burundi, Tanzania, Zambia and Angola. Certain of the Company’s operations manufacture, or contract to manufacture, products for which the Conflict Minerals are necessary to the functionality or production of those products.
    The Company has conducted a reasonable country of origin inquiry regarding the Conflict Minerals. This inquiry was reasonably designed to determine whether any of the Conflict Minerals originated in the Covered Countries and whether any of the Conflict Minerals may be from recycled or scrap sources. The Company’s reasonable country of origin inquiry was part of its due diligence on the source and chain of custody of the Conflict Minerals.
    Based on this reasonable country of origin inquiry, the Company has reason to believe that certain of its necessary Conflict Minerals may have originated in the Covered Countries and are not from recycled or scrap sources. The Company’s due diligence on the source and chain of custody of the Conflict Minerals, including its efforts to determine the countries of origin of the Conflict Minerals, are described in the Company’s Conflict Minerals Report.

    Item 1.02 Exhibit

    As specified in Section 3, Item 3.01 of this Form SD, the Company is hereby filing its Conflict Minerals Report as Exhibit 1.01 to this report.
    Section 2 — Resource Extraction Issuer Disclosure

    Item 2.01 Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 — Exhibits
     
    Item 3.01 Exhibits

    The following exhibit is filed as part of this report.  
    Exhibit
    No.
      Description
    1.01  
    Conflict Minerals Report of Envista Holdings Corporation.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
    ENVISTA HOLDINGS CORPORATION
     
    By: /s/ Mark Nance  May 30, 2025
     Mark Nance  
     Senior Vice President, General Counsel and Secretary  
     





    EXHIBIT INDEX
     
    Exhibit
    No.
      Description
    1.01  Conflict Minerals Report of Envista Holdings Corporation.
     


    Get the next $NVST alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVST

    DatePrice TargetRatingAnalyst
    5/27/2025$23.00Neutral → Outperform
    Robert W. Baird
    12/4/2024$20.00Underperform
    Mizuho
    10/31/2024$16.00 → $23.00Underperform → Market Perform
    Leerink Partners
    10/8/2024$20.00Equal Weight
    Wells Fargo
    8/8/2024$23.00 → $16.00Overweight → Neutral
    JP Morgan
    4/26/2024$33.00 → $21.00Overweight → Equal-Weight
    Morgan Stanley
    2/26/2024$19.00Underperform
    Leerink Partners
    2/9/2024$30.00 → $23.00Buy → Hold
    Jefferies
    More analyst ratings

    $NVST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Envista Reports Second Quarter 2025 Results

    BREA, Calif., July 31, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended June 27, 2025. "Envista achieved accelerated growth across all of our businesses and major geographies in the second quarter," said Paul Keel, CEO. "This allowed us to further increase investments in growth, operations, and people, while also delivering strong improvement in year-over-year profitability. Based on the first half momentum and results, we are raising our full year guidance for 2025." Financial Highlights: Q2 2025 highlightsSales were

    7/31/25 4:05:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Schedules Second Quarter 2025 Earnings Call

    BREA, Calif., July 9, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its second quarter 2025 on Thursday, July 31, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation. You can access the conference call by diali

    7/9/25 4:10:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Announces Participation in Stifel 2025 Jaws & Paws Conference

    BREA, Calif., May 22, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced that the company will participate in the Stifel 2025 Jaws & Paws Conference. The fireside chat will take place on Wednesday, May 28, 2025, from 1:50 – 2:20 pm ET. A live audio webcast of the event, along with an archived replay, will be available in the Investors section of the Envista website at https://investors.envistaco.com/.  ABOUT ENVISTA HOLDINGS CORPORATION Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS

    5/22/25 4:15:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pierce James Andrew was granted 9,155 shares (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    7/16/25 4:17:26 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Pierce James Andrew

    3 - Envista Holdings Corp (0001757073) (Issuer)

    7/16/25 4:15:51 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Director Gallahue Kieran was granted 10,450 shares, increasing direct ownership by 31% to 44,680 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    6/12/25 4:55:53 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Keel Paul A bought $506,100 worth of shares (30,000 units at $16.87), increasing direct ownership by 8% to 402,605 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    8/14/24 4:40:20 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Hammes Eric D. bought $400,608 worth of shares (24,532 units at $16.33) (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    8/13/24 6:01:10 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Conley Eric bought $50,015 worth of shares (2,185 units at $22.89), increasing direct ownership by 5% to 47,376 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    11/20/23 5:49:32 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Envista upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Envista from Neutral to Outperform and set a new price target of $23.00

    5/27/25 9:05:49 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Mizuho initiated coverage on Envista with a new price target

    Mizuho initiated coverage of Envista with a rating of Underperform and set a new price target of $20.00

    12/4/24 7:46:09 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Envista from Underperform to Market Perform and set a new price target of $23.00 from $16.00 previously

    10/31/24 6:27:39 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Envista Holdings Corporation

    SCHEDULE 13G/A - Envista Holdings Corp (0001757073) (Subject)

    8/14/25 4:20:32 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Envista Holdings Corporation

    SCHEDULE 13G - Envista Holdings Corp (0001757073) (Subject)

    8/5/25 3:59:29 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Envista Holdings Corporation

    S-8 - Envista Holdings Corp (0001757073) (Filer)

    8/1/25 4:14:20 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Compass Diversified Announces Stephen Keller as Chief Financial Officer

    WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to facilitate a seamless transition. In his new role, Mr. Keller will lead CODI's finance organization, including accounting, planning, treasury, tax, reporting, and investor relations. He b

    8/26/24 6:00:00 AM ET
    $AVY
    $CODI
    $NVST
    Containers/Packaging
    Consumer Discretionary
    Home Furnishings
    Medical/Dental Instruments

    Envista Holdings Corporation Announces Key Leadership Appointments

    BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the following key leadership appointments: Eric Hammes joins Envista as Chief Financial OfficerStefan Nilsson joins Envista as President, Nobel BiocareVeronica Acurio joins Envista as President, Ormco"It is a pleasure to welcome this trio of successful leaders to Envista," said Paul Keel, Chief Executive Officer. "Each brings experience in dental along with a proven track record of continuous improvement, leading with purpose, and creating value for all stakeholders. Today's an

    7/15/24 4:10:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Envista Holdings Corporation

    SC 13G - Envista Holdings Corp (0001757073) (Subject)

    11/8/24 12:09:03 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Envista Holdings Corporation (Amendment)

    SC 13G/A - Envista Holdings Corp (0001757073) (Subject)

    2/15/24 10:19:33 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Envista Holdings Corporation

    SC 13G - Envista Holdings Corp (0001757073) (Subject)

    2/14/24 4:08:38 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Financials

    Live finance-specific insights

    View All

    Envista Reports Second Quarter 2025 Results

    BREA, Calif., July 31, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended June 27, 2025. "Envista achieved accelerated growth across all of our businesses and major geographies in the second quarter," said Paul Keel, CEO. "This allowed us to further increase investments in growth, operations, and people, while also delivering strong improvement in year-over-year profitability. Based on the first half momentum and results, we are raising our full year guidance for 2025." Financial Highlights: Q2 2025 highlightsSales were

    7/31/25 4:05:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Schedules Second Quarter 2025 Earnings Call

    BREA, Calif., July 9, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its second quarter 2025 on Thursday, July 31, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation. You can access the conference call by diali

    7/9/25 4:10:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Reports First Quarter 2025 Results

    BREA, Calif., May 1, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended March 28, 2025. "In the first quarter, Envista delivered results in line with our expectations building on the momentum established across the second half of 2024," said Paul Keel, CEO. "We continued to drive improvements across our three priority areas of growth, operations, and people. This was a solid start to the year, and we are maintaining our 2025 guidance." Q1 2025 financial highlights: Sales were $617 million, with core sales increasing 0.2%

    5/1/25 4:05:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care